549 related articles for article (PubMed ID: 32394767)
1. Glioblastoma multiforme: novel therapeutic targets.
Muir M; Gopakumar S; Traylor J; Lee S; Rao G
Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
[TBL] [Abstract][Full Text] [Related]
2. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
3. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA and extracellular vesicles in glioblastoma: small but powerful.
Rooj AK; Mineo M; Godlewski J
Brain Tumor Pathol; 2016 Apr; 33(2):77-88. PubMed ID: 26968172
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
6. Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.
Morisse MC; Jouannet S; Dominguez-Villar M; Sanson M; Idbaih A
Expert Rev Neurother; 2018 Sep; 18(9):729-737. PubMed ID: 30099909
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic gene therapy in the treatment of malignant gliomas.
Gatson NN; Chiocca EA; Kaur B
Neurosci Lett; 2012 Oct; 527(2):62-70. PubMed ID: 22906922
[TBL] [Abstract][Full Text] [Related]
8. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
Rivera M; Bander ED; Cisse B
World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
[TBL] [Abstract][Full Text] [Related]
10. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
11. Myeloid Cells in Glioblastoma Microenvironment.
De Leo A; Ugolini A; Veglia F
Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
[TBL] [Abstract][Full Text] [Related]
12. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Londhe VY; Date V
Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
[TBL] [Abstract][Full Text] [Related]
13. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
14. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
15. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.
Habib A; Pease M; Kodavali CV; Amankulor N; Zinn PO
J Neurooncol; 2021 Jan; 151(2):103-112. PubMed ID: 33394264
[TBL] [Abstract][Full Text] [Related]
16. The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma.
Goenka A; Tiek D; Song X; Huang T; Hu B; Cheng SY
Cells; 2021 Feb; 10(3):. PubMed ID: 33668200
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma Therapy in the Age of Molecular Medicine.
Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
[TBL] [Abstract][Full Text] [Related]
19. Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.
Yu W; Liang S; Zhang C
Neuromolecular Med; 2018 Dec; 20(4):452-474. PubMed ID: 30182330
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
Anthony C; Mladkova-Suchy N; Adamson DC
Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
[No Abstract] [Full Text] [Related]
[Next] [New Search]
